Collegium Pharmaceutical (NASDAQ:COLL) Shares Down 6.5% – Here’s Why

Collegium Pharmaceutical, Inc. (NASDAQ:COLL)’s stock price was down 6.5% during mid-day trading on Monday . The company traded as low as $27.70 and last traded at $27.5610. Approximately 156,600 shares changed hands during trading, a decline of 67% from the average session volume of 481,368 shares. The stock had previously closed at $29.47.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. Zacks Research downgraded Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 28th. Wall Street Zen cut shares of Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Saturday. Needham & Company LLC decreased their price objective on Collegium Pharmaceutical from $56.00 to $46.00 and set a “buy” rating on the stock in a report on Thursday. Truist Financial raised Collegium Pharmaceutical to a “strong-buy” rating in a report on Monday, June 15th. Finally, Piper Sandler reaffirmed a “neutral” rating and set a $43.00 price target (down from $45.00) on shares of Collegium Pharmaceutical in a report on Friday. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $52.60.

Collegium Pharmaceutical Stock Performance

The company has a debt-to-equity ratio of 3.32, a current ratio of 1.03 and a quick ratio of 0.84. The company has a market capitalization of $886.12 million, a P/E ratio of 21.96 and a beta of 0.73. The company has a fifty day moving average price of $34.78 and a two-hundred day moving average price of $37.01.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings results on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.72 by $0.20. The firm had revenue of $199.88 million during the quarter, compared to the consensus estimate of $199.62 million. Collegium Pharmaceutical had a net margin of 5.93% and a return on equity of 91.43%. The company’s revenue for the quarter was up 6.3% on a year-over-year basis. During the same quarter last year, the firm earned $1.68 earnings per share. Equities analysts forecast that Collegium Pharmaceutical, Inc. will post 6.76 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Collegium Pharmaceutical

Hedge funds and other institutional investors have recently bought and sold shares of the company. BlackRock Inc. acquired a new position in shares of Collegium Pharmaceutical in the 2nd quarter valued at about $196,972,000. Deutsche Bank AG bought a new stake in shares of Collegium Pharmaceutical during the second quarter worth about $1,270,000. Bank of New York Mellon Corp purchased a new stake in shares of Collegium Pharmaceutical in the second quarter worth approximately $8,506,000. State of Wyoming purchased a new stake in Collegium Pharmaceutical in the 2nd quarter valued at $218,000. Finally, One Wealth Advisors LLC purchased a new stake in shares of Collegium Pharmaceutical in the second quarter valued at about $310,000.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.